FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 57 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q2 2017. The put-call ratio across all filers is 21.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $929,000 | -51.7% | 305,500 | -62.2% | 0.35% | -51.7% |
Q2 2019 | $1,923,000 | -36.5% | 808,000 | 0.0% | 0.72% | -44.7% |
Q1 2019 | $3,030,000 | +4.4% | 808,000 | 0.0% | 1.31% | -9.4% |
Q4 2018 | $2,901,000 | -37.3% | 808,000 | 0.0% | 1.44% | -24.1% |
Q3 2018 | $4,630,000 | +173.5% | 808,000 | +139.1% | 1.90% | +139.7% |
Q2 2018 | $1,693,000 | -1.6% | 338,000 | +0.7% | 0.79% | -5.3% |
Q1 2018 | $1,721,000 | -18.8% | 335,500 | -4.9% | 0.84% | -26.7% |
Q4 2017 | $2,120,000 | +47.6% | 352,741 | +36.4% | 1.14% | +28.0% |
Q3 2017 | $1,436,000 | -13.0% | 258,667 | -27.3% | 0.89% | -24.2% |
Q2 2017 | $1,650,000 | +2.4% | 355,667 | +9.2% | 1.18% | -13.6% |
Q1 2017 | $1,612,000 | -45.8% | 325,667 | +21.5% | 1.36% | -47.9% |
Q4 2016 | $2,976,000 | +15.6% | 268,067 | -3.6% | 2.62% | +45.8% |
Q3 2016 | $2,575,000 | +110.5% | 278,067 | +44.4% | 1.79% | +85.0% |
Q2 2016 | $1,223,000 | +58.0% | 192,567 | +62.3% | 0.97% | +45.1% |
Q1 2016 | $774,000 | +57.0% | 118,671 | +95.3% | 0.67% | +52.2% |
Q4 2015 | $493,000 | – | 60,770 | – | 0.44% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DSC Advisors, L.P. | 1,667,377 | $15,440,000 | 9.38% |
GREAT POINT PARTNERS LLC | 2,769,425 | $25,645,000 | 6.54% |
Opaleye Management Inc. | 630,000 | $5,834,000 | 3.05% |
Vivo Capital, LLC | 855,000 | $7,917,000 | 2.47% |
DAFNA Capital Management LLC | 278,067 | $2,575,000 | 1.79% |
RA Capital Management | 1,820,138 | $16,854,000 | 1.74% |
SENZAR ASSET MANAGEMENT, LLC | 523,397 | $4,846,656,000 | 1.25% |
Perceptive Advisors | 1,373,284 | $12,717,000 | 0.82% |
Monashee Investment Management LLC | 225,000 | $2,084,000 | 0.73% |
NEXTHERA CAPITAL LP | 125,000 | $1,158,000 | 0.71% |